207 related articles for article (PubMed ID: 27188752)
1. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies.
Galassi G; Tondelli M; Ariatti A; Benuzzi F; Nichelli P; Valzania F
Int J Neurosci; 2017 May; 127(5):439-447. PubMed ID: 27188752
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study.
Niermeijer JM; Fischer K; Eurelings M; Franssen H; Wokke JH; Notermans NC
Neurology; 2010 Feb; 74(5):406-12. PubMed ID: 20124206
[TBL] [Abstract][Full Text] [Related]
3. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
Magy L; Kaboré R; Mathis S; Lebeau P; Ghorab K; Caudie C; Vallat JM
J Immunol Res; 2015; 2015():450391. PubMed ID: 26065001
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
[TBL] [Abstract][Full Text] [Related]
6. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
8. Nerve ultrasound findings in neuropathy associated with anti-myelin-associated glycoprotein antibodies.
Lucchetta M; Padua L; Granata G; Luigetti M; Campagnolo M; Dalla Torre C; Coraci D; Sabatelli M; Briani C
Eur J Neurol; 2015 Jan; 22(1):193-202. PubMed ID: 25174585
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
10. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?
Capasso M; Torrieri F; Di Muzio A; De Angelis MV; Lugaresi A; Uncini A
Clin Neurophysiol; 2002 Mar; 113(3):346-53. PubMed ID: 11897535
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
12. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases.
Larue S; Bombelli F; Viala K; Neil J; Maisonobe T; Bouche P; Musset L; Fournier E; Léger JM
Eur J Neurol; 2011 Jun; 18(6):899-905. PubMed ID: 21199182
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
14. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
15. Clinical, electrophysiological and immunological study of peripheral nerves in Egyptian patients with monoclonal gammopathies.
El-Difrawy MM; Zaki NE; Marouf HM; Ayad MW; Farag AM
Int J Hematol; 2012 Jan; 95(1):71-6. PubMed ID: 22193843
[TBL] [Abstract][Full Text] [Related]
16. [Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients' cohort].
Launay M; Delmont E; Benaim C; Sacconi S; Butori C; Desnuelle C
Rev Neurol (Paris); 2009 Dec; 165(12):1071-9. PubMed ID: 19487003
[TBL] [Abstract][Full Text] [Related]
17. IgM MGUS associated with anti-MAG neuropathy: a single institution experience.
Talamo G; Mir MA; Pandey MK; Sivik JK; Raheja D
Ann Hematol; 2015 Jun; 94(6):1011-6. PubMed ID: 25572169
[TBL] [Abstract][Full Text] [Related]
18. Are electrophysiological features related to disability in patients with anti-MAG neuropathy?
Gesquière-Dando A; Delmont E; Launay M; Boucraut J; Attarian S
Neurophysiol Clin; 2017 Feb; 47(1):75-81. PubMed ID: 28161089
[TBL] [Abstract][Full Text] [Related]
19. Determinants of health-related quality of life in anti-MAG neuropathy: a cross-sectional multicentre European study.
Delmont E; Hiew FL; Cassereau J; Aubé-Nathier AC; Grapperon AM; Attarian S; Rajabally YA
J Peripher Nerv Syst; 2017 Mar; 22(1):27-33. PubMed ID: 27868289
[TBL] [Abstract][Full Text] [Related]
20. Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases.
Ellie E; Vital A; Steck A; Boiron JM; Vital C; Julien J
J Neurol; 1996 Jan; 243(1):34-43. PubMed ID: 8869385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
